Last updated on October 2017

The OLYMPUS Study - Optimized DeLivery of Mitomycin for Primary UTUC Study


Brief description of study

The study is investigating the ability of UroGen's MitoGel™ procedure to treat urothelial carcinoma tumors from the upper urinary tract. If this treatment will prove to be effective this will lead to the development of a new treatment approach for patients suffering from Low Grade Upper Urinary Urothelial Carcinoma (UTUC).

Detailed Study Description

Trial TC-UT-03 is a prospective, single-arm trial, designed to assess the efficacy, safety, and tolerability of treatment with MitoGel™ instilled in the upper urinary system of patients with non-invasive low-grade (LG), UTUC. Upon signing of informed consent, the patients will undergo a screening visit for eligibility evaluation. Eligible patients will be treated with MitoGel™ once weekly for a total of 6 times; in a retrograde fashion. Patients who will demonstrate CR will be treated with MitoGel™ once monthly as a maintenance therapy for a total of 11 instillations or up to the first recurrence whichever comes first. Five (5) weeks (± 1 w) following the last instillation, the PDE Visit, during which safety and efficacy will be assessed, will take place. During this visit, the ablative effect of the MitoGel™ will be assessed visually, by upper tract washed urine cytology, and if there are remaining tumors, by biopsy or brush biopsy if technically feasible. Patient demonstrating CR at PDE will undergo monthly maintenance instillations of MitoGel™ up to 11 months post PDE. Safety follow-up for these patients will be done until one month post last instillation or at the end of the follow-up period in FU visit 12, which is the earlier. For patients who did not demonstrate Complete Response, to the extent that it is possible, all remaining tumors lesions will be biopsied. The patients shall undergo any additional surgical or other treatment the PI decides deem necessary to remove remaining tumor. An independent Data Monitoring Committee (DMC) was assigned to this trial. Accumulating safety, tolerability and efficacy data will be monitored periodically by the DMC according to a pre-specified process and frequency detailed in the DMC charter.

Clinical Study Identifier: NCT02793128

Contact Investigators or Research Sites near you

Start Over

Josh Logan, MD

Alaska Urological Institute
Anchorage, AK United States
  Connect »

Mitchell Humphreys, M.D.

Mayo Clinic Hospital
Phoenix, AZ United States
  Connect »

Marc Dall'Era, MD

University of California
Davis, CA United States
  Connect »

Brian Hu, M.D.

Loma Linda Cancer Center
Loma Linda, CA United States
  Connect »

Karim Chamie, MD

University of California
Los Angeles, CA United States
  Connect »

Jennifer Linehan, M.D.

Providence Medical Institute
Santa Monica, CA United States
  Connect »

Raymond Pak, M.D.

Mayo Clinic Florida
Jacksonville, FL United States
  Connect »

Hristos Kaimakliotis, M.D.

Indiana University School of Medicine
Indianapolis, IN United States
  Connect »

Mike O'Donnell, M.D.

University of Iowa
Iowa City, IA United States
  Connect »

Phillip Pierorazio, MD

John Hopkins University
Baltimore, MD United States
  Connect »

Alon Weizer, M.D.

University of Michigan Comprehensive Cancer Center
Ann Arbor, MI United States
  Connect »

Christopher Weight, M.D.

University of Minnesota
Minneapolis, MN United States
  Connect »

Lance Mynderse, M.D.

Mayo Clinic health system
Rochester, MN United States
  Connect »

Ojas Shah, M.D.

Herbert Irving Comprehensive Cancer Center, Columbia University Medical Center
New York, NY United States
  Connect »

Douglas S Scherr, MD

Weill Cornell Medical Center
New York, NY United States
  Connect »

Joshua Stern, MD

Montefiore Medical Center (Albert Einstein)
The Bronx, NY United States
  Connect »

Michael Woods, MD

University of north carolina - chapel hill
Chapel Hill, NC United States
  Connect »

Brant Inman, M.D.

Duke University
Durham, NC United States
  Connect »

Andrew Stephenson, M.D.

Cleveland Clinic
Cleveland, OH United States
  Connect »

Ahmad Shabsigh, MD

The Ohio State University Wexner Medical Center
Columbus, OH United States
  Connect »

Jay Raman, M.D.

Penn State College of Medicine
Hershey, PA United States
  Connect »

Scott Hubosky, M.D.

Thomas Jefferson University Hospitals
Philadelphia, PA United States
  Connect »

Jefferey Gingrich, MD

University of Pittsburgh Medical Center
Pittsburgh, PA United States
  Connect »

Surena Matin, MD

MD Anderson
Houston, TX United States
  Connect »

Guilherme Godoy, MD

Baylor College of Medicine
Houston, TX United States
  Connect »

Michael Williams, M.D.

Sentara Norfolk General Hospital
Norfolk, VA United States
  Connect »

Nir Kleinmann, M.D.

Sheba Medical Center
Ramat Gan, Israel
  Connect »